Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Protease measurement assays aspartyl renal juxtaglomerular cells sodium depletion blood volume pressure .beta.-adrenergic stimulation angiotensinogens angiotensins I II converting ACE monomeric zinc metalloenzymes vascular endothelium messengers RAS vasoconstrictor peripheral hypertension receptors blockers fluorescence fluorescent fluorometric atherosclerosis endocrinology
- Product Overview:
Renin is an aspartyl protease of approximately 40 kDa that is released in active form from renal juxtaglomerular cells in response to sodium depletion, decreased blood volume and blood pressure, and b-adrenergic stimulation.{12331,13007,12970} Renin catalyzes the initial and rate limiting step in the renin-angiotensin system (RAS) pathway, converting angiotensinogen into angiotensin I. Angiotensin Converting Enzyme (ACE) subsequently converts angiotensin I to angiotensin II, which is a potent vasoconstrictor. Cayman’s Renin Inhibitor Screening Assay Kit provides a convenient assay in a 96-well format for evaluating human renin inhibitors. The assay utilizes a renin-based synthetic peptide substrate which incorporates the fluorophore EDANS at one end and an EDAN-quenching molecule (Dabcyl) at the other end.{12969} After cleavage by renin, the peptide-EDANS product is released yielding bright fluorescence which can be easily analyzed using excitation wavelengths of 335-345 nm and emission wavelengths of 485-510 nm. The assay kit includes recombinant human renin (sufficient for 100 reactions), substrate, buffers, and complete instructions.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.